"RANK Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.
| Descriptor ID |
D053245
|
| MeSH Number(s) |
D12.644.276.374.750.562 D12.776.467.374.750.562 D23.529.374.750.562
|
| Concept/Terms |
RANK Ligand- RANK Ligand
- OPGL Protein
- Osteoclast Differentiation Factor
- Differentiation Factor, Osteoclast
- Osteoprotegerin Ligand
- Receptor Activator of Nuclear Factor-kappa B Ligand
- Receptor Activator of Nuclear Factor kappa B Ligand
- Receptor Activator of Nuclear Factor-kappaB Ligand
- Receptor Activator of Nuclear Factor kappaB Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 11
- TNF Superfamily, Member 11
- RANKL Protein
- Tumor Necrosis Factor-Related Activation-Induced Cytokine
- Tumor Necrosis Factor Related Activation Induced Cytokine
- CD254 Antigen
- Antigen, CD254
- TRANCE Protein
|
Below are MeSH descriptors whose meaning is more general than "RANK Ligand".
Below are MeSH descriptors whose meaning is more specific than "RANK Ligand".
This graph shows the total number of publications written about "RANK Ligand" by people in this website by year, and whether "RANK Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 4 | 2 | 6 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "RANK Ligand" by people in Profiles.
-
ATRX silences Cartpt expression in osteoblastic cells during skeletal development. J Clin Invest. 2025 Jan 02; 135(1).
-
Histopathologic and transcriptomic phenotypes of a conditional RANKL transgenic mouse thymus. Cytokine. 2022 12; 160:156022.
-
Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat Commun. 2022 06 27; 13(1):3684.
-
Induced Differentiation of M Cell-like Cells in Human Stem Cell-derived Ileal Enteroid Monolayers. J Vis Exp. 2019 07 26; (149).
-
Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland. Cytokine. 2019 11; 123:154745.
-
Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-?B and MAPK pathways. J Cell Physiol. 2019 08; 234(10):17600-17611.
-
BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells. Sci Rep. 2018 05 31; 8(1):8475.
-
Inhibitory effect of sulphated polysaccharide porphyran (isolated from Porphyra yezoensis) on RANKL-induced differentiation of RAW264.7 cells into osteoclasts. Phytother Res. 2018 Mar; 32(3):452-458.
-
Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-?B and Its Ligand. ChemMedChem. 2017 10 20; 12(20):1697-1702.
-
Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017 Jul; 164(1):57-67.